• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项针对接受调强放疗或三维放疗的头颈癌患者唾液功能保留情况的前瞻性研究:初步结果。

A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.

作者信息

Chao K S, Deasy J O, Markman J, Haynie J, Perez C A, Purdy J A, Low D A

机构信息

Radiation Oncology Center, Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63110, USA.

出版信息

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16. doi: 10.1016/s0360-3016(00)01441-3.

DOI:10.1016/s0360-3016(00)01441-3
PMID:11240231
Abstract

OBJECTIVES

In a prospective clinical study, we tested the hypothesis that sparing the parotid glands may result in significant objective and subjective improvement of xerostomia in patients with head-and-neck cancers. The functional outcome 6 months after the completion of radiation therapy is presented.

METHODS AND MATERIALS

From February 1997 to February 1999, 41 patients with head-and-neck cancers were enrolled in a prospective salivary function study. Inverse-planning intensity-modulated radiation therapy (IMRT) was used to treat 27 patients, and forward-planning three-dimensional radiation therapy in 14. To avoid potential bias in data interpretation, only patients whose submandibular glands received greater than 50 Gy were eligible. Attempts were made to spare the superficial lobe of the parotid glands to avoid underdosing tumor targets in the parapharyngeal space; however, the entire parotid volume was used to compute dose-volume histograms (DVHs) for this analysis. DVHs were computed for each gland separately. Parotid function was assessed objectively by measuring stimulated and unstimulated saliva flow before and 6 months after the completion of radiation therapy. Measurements were converted to flow rate (mL/min) and normalized relative to that before treatment. The corresponding quality-of-life (QOL) outcome was assessed by five questions regarding the patient's oral discomfort and eating/speaking problems.

RESULTS

We observed a correlation between parotid mean dose and the fractional reduction of stimulated saliva output at 6 months after the completion of radiation therapy. We further examined whether the functional outcome could be modeled as a function of dose. Two models were found to describe the dose-response data well. The first model assumed that each parotid gland is comprised of multiple independent parallel functional subunits (corresponding to computed tomography voxels) and that each gland contributes equally to overall flow, and that saliva output decreases exponentially as a quadratic function of irradiation dose to each voxel. The second approach uses the equivalent uniform dose (EUD) metrics, which assumes loss of salivary function with increase in EUD for each parotid gland independently. The analysis suggested that the mean dose to each parotid gland is a reasonable indicator for the functional outcome of each gland. The corresponding exponential coefficient was 0.0428/Gy (95% confidence interval: 0.01, 0.09). The QOL questions on eating/speaking function were significantly correlated with stimulated and unstimulated saliva flow at 6 months. In a multivariate analysis, a toxicity score derived from the model based on radiation dose to the parotid gland was found to be the sole significant predictive factor for xerostomia. Neither radiation technique (IMRT vs. non-IMRT) nor chemotherapy (yes or no) independently influenced the functional outcome of the salivary glands.

CONCLUSION

Sparing of the parotid glands translates into objective and subjective improvement of both xerostomia and QOL scores in patients with head-and-neck cancers receiving radiation therapy. Modeling results suggest an exponential relationship between saliva flow reduction and mean parotid dose for each gland. We found that the stimulated saliva flow at 6 months after treatment is reduced exponentially, for each gland independently, at a rate of approximately 4% per Gy of mean parotid dose.

摘要

目的

在一项前瞻性临床研究中,我们检验了以下假设:对头颈部癌患者保留腮腺可能会使口干症在客观和主观方面得到显著改善。本文呈现了放射治疗结束6个月后的功能结果。

方法与材料

1997年2月至1999年2月,41名头颈部癌患者参与了一项前瞻性唾液功能研究。采用逆向计划调强放射治疗(IMRT)治疗27例患者,14例采用正向计划三维放射治疗。为避免数据解读中的潜在偏差,仅下颌下腺接受剂量大于50 Gy的患者符合条件。尽量保留腮腺浅叶以避免咽旁间隙肿瘤靶区剂量不足;然而,整个腮腺体积用于计算剂量体积直方图(DVH)以进行此分析。分别为每个腺体计算DVH。通过在放射治疗结束前和结束后6个月测量刺激和非刺激唾液流量来客观评估腮腺功能。测量值转换为流速(mL/min)并相对于治疗前进行标准化。通过关于患者口腔不适和进食/说话问题的五个问题评估相应的生活质量(QOL)结果。

结果

我们观察到放射治疗结束6个月时腮腺平均剂量与刺激唾液分泌量的分数减少之间存在相关性。我们进一步研究功能结果是否可以建模为剂量的函数。发现有两个模型能很好地描述剂量反应数据。第一个模型假设每个腮腺由多个独立的平行功能亚单位(对应于计算机断层扫描体素)组成,且每个腺体对总体流量的贡献相同,并且唾液分泌量随每个体素照射剂量的二次函数呈指数下降。第二种方法使用等效均匀剂量(EUD)指标,该指标假设每个腮腺的唾液功能随EUD增加而丧失。分析表明每个腮腺的平均剂量是每个腺体功能结果的合理指标。相应的指数系数为0.0428/Gy(95%置信区间:0.01,0.09)。关于进食/说话功能的QOL问题与6个月时的刺激和非刺激唾液流量显著相关。在多变量分析中,发现基于腮腺放射剂量的模型得出的毒性评分是口干症的唯一显著预测因素。放射技术(IMRT与非IMRT)和化疗(是或否)均未独立影响唾液腺的功能结果。

结论

对头颈部癌接受放射治疗的患者保留腮腺可使口干症和QOL评分在客观和主观方面均得到改善。建模结果表明每个腺体的唾液流量减少与腮腺平均剂量之间呈指数关系。我们发现治疗后6个月时每个腺体的刺激唾液流量独立地以每Gy腮腺平均剂量约4%的速率呈指数下降。

相似文献

1
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.一项针对接受调强放疗或三维放疗的头颈癌患者唾液功能保留情况的前瞻性研究:初步结果。
Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16. doi: 10.1016/s0360-3016(00)01441-3.
2
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.头颈部癌放疗患者唾液功能的剂量-体积建模
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1055-69. doi: 10.1016/j.ijrobp.2004.12.076.
3
Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.头颈部癌逆向计划调强放射治疗(IMRT)后口腔健康相关生活质量和唾液流速的保留情况
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):663-73. doi: 10.1016/S0360-3016(03)01571-2.
4
Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.头颈部癌的适形和调强放疗可保护唾液腺并改善靶区照射。
World J Surg. 2003 Jul;27(7):832-7. doi: 10.1007/s00268-003-7105-6.
5
Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.用高锝酸盐定量闪烁扫描术评估调强放疗治疗头颈部肿瘤后唾液腺功能
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):175-84. doi: 10.1016/s0360-3016(03)01437-8.
6
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.头颈部癌适形和调强放疗后腮腺的剂量、体积与功能关系
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87. doi: 10.1016/s0360-3016(99)00247-3.
7
Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.头颈部癌症患者接受或不接受对侧颌下腺保护的调强放疗后唾液腺剂量对唾液分泌和口干程度恢复的影响:一项纵向研究。
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1479-87. doi: 10.1016/j.ijrobp.2010.07.1990. Epub 2010 Oct 8.
8
Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: evidence of significant recovery effect.描述调强放疗腮腺照射时流量减少的现象学模型:显著恢复效应的证据
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):178-85. doi: 10.1016/j.ijrobp.2004.02.041.
9
Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.头颈部癌保留腮腺调强放疗后的生活质量:一项前瞻性纵向研究。
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):61-70. doi: 10.1016/s0360-3016(03)00361-4.
10
A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.一项II期研究,旨在评估氨磷汀在对头颈部癌进行调强放射治疗以保留腮腺唾液时,对保留下颌下腺/舌下腺唾液的疗效。
Semin Oncol. 2004 Dec;31(6 Suppl 18):25-8. doi: 10.1053/j.seminoncol.2004.12.008.

引用本文的文献

1
Patient-Specific Deep Reinforcement Learning for Automatic Replanning in Head-and-Neck Cancer Proton Therapy.用于头颈癌质子治疗自动再计划的患者特异性深度强化学习
ArXiv. 2025 Aug 11:arXiv:2506.10073v2.
2
Summary of the best evidence for perioperative enteral nutrition management in patients with laryngeal cancer.喉癌患者围手术期肠内营养管理的最佳证据总结
Support Care Cancer. 2025 May 29;33(6):512. doi: 10.1007/s00520-025-09546-y.
3
Non‑endemic non‑keratinizing nasopharyngeal carcinoma: Long‑term toxicity following chemoradiation.
非地方性非角化性鼻咽癌:放化疗后的长期毒性
Oncol Lett. 2025 Apr 9;29(6):283. doi: 10.3892/ol.2025.15029. eCollection 2025 Jun.
4
Local control of pediatric head and neck sarcoma with free flap reconstruction obviating the need for radiotherapy: a case report.采用游离皮瓣重建避免放疗实现小儿头颈部肉瘤的局部控制:1例病例报告
Transl Pediatr. 2024 Aug 31;13(8):1503-1509. doi: 10.21037/tp-24-4. Epub 2024 Aug 27.
5
Randomized Double-Blind Placebo-Controlled Study of Salivary Substitute with Enzymatic System for Xerostomia in Patients Irradiated in Head and Neck Region.随机双盲安慰剂对照研究唾液替代物与酶系统治疗头颈部放疗患者口干症
Curr Oncol. 2024 Feb 18;31(2):1102-1112. doi: 10.3390/curroncol31020082.
6
Development of Prediction Model for Mean Parotid Dose of HNC Undergoing Radiotherapy - A Single Institutional Study.头颈部癌放疗患者腮腺平均剂量预测模型的建立——一项单机构研究
J Med Phys. 2023 Jul-Sep;48(3):274-280. doi: 10.4103/jmp.jmp_52_23. Epub 2023 Sep 18.
7
Deep-neural network approaches for predicting 3D dose distribution in intensity-modulated radiotherapy of the brain tumors.用于预测脑肿瘤调强放疗中三维剂量分布的深度神经网络方法。
J Appl Clin Med Phys. 2024 Mar;25(3):e14197. doi: 10.1002/acm2.14197. Epub 2023 Nov 7.
8
ROE (Radiotherapy Outcomes Estimator): An open-source tool for optimizing radiotherapy prescriptions.ROE(放射治疗结果估算器):一种用于优化放射治疗方案的开源工具。
Comput Methods Programs Biomed. 2023 Dec;242:107833. doi: 10.1016/j.cmpb.2023.107833. Epub 2023 Oct 14.
9
FLASH instead of proton arc therapy is a more promising advancement for the next generation proton radiotherapy.闪疗而非质子弧形治疗是下一代质子放射治疗更有前景的进展。
J Appl Clin Med Phys. 2023 Aug;24(8):e14091. doi: 10.1002/acm2.14091. Epub 2023 Jul 11.
10
The Role of Dental Practitioners in the Management of Oncology Patients: The Head and Neck Radiation Oncology Patient and the Medical Oncology Patient.牙科医生在肿瘤患者管理中的作用:头颈部放射肿瘤患者和内科肿瘤患者。
Dent J (Basel). 2023 May 17;11(5):136. doi: 10.3390/dj11050136.